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 44 
To the editor: the optimal management of cancer patients is increasingly dependent on individualized 45 
treatments guided by tumor sequencing data. As comprehensive genomic tests become routine in many 46 
disease settings and academic centers promote omics-guided clinical trial recruitment, accurate and 47 
scalable data interpretation represents a major challenge. The meticulous task of matching tumor 48 
alterations with approved or experimental therapies relies heavily on the expertise of each center. 49 
Unsurprisingly, we see similar sequencing results leading to different clinical recommendations1. While 50 
the number of drug biomarkers with target specificities is constantly growing, these disparities are likely to 51 
escalate, which may ultimately impair patients’ outcomes and research progress. Access to commercial 52 
test results does not simplify decision-making, as they often deliver generic reports that lack the 53 
 
necessary information to prioritize emerging therapies. In addition, data interpretation must also contend 54 
with incidental germline findings, which further complicates the process. Medical teams face the extra 55 
burden of manually searching for the latest scientific evidence associated with detected gene alterations, 56 
which is a complex, time consuming and error-prone task. Here we argue for the need to streamline 57 
expert-driven genomic data interpretation and reporting workflows and employ user-friendly decision 58 
support tools that foster interactive treatment planning. 59 
In response, we have developed the Molecular Tumor Board Portal (MTBP), a clinical decision support 60 
system that unifies the analysis of sequencing results across seven European comprehensive cancer 61 
centers under the umbrella of the Cancer Core Europe (CCE) network2. The portal is used to select 62 
candidates for the Basket of Baskets trial (NCT03767075), a modular multi-arm study for genomically-63 
defined populations, as well as other clinical studies with active recruitment across CCE sites. Following a 64 
process agreed among CCE experts, the system automates omics data capture, interpretation and 65 
reporting, and creates a framework to share and harness results (Figure). MTBP reports are discussed 66 
during weekly virtual meetings where multidisciplinary representatives from each CCE center decide on 67 
clinical interventions. These reports are patient-centric web-based documents with the annotations 68 
supporting a given variant classification and the complete provenance of all assertions readily accessible 69 
through interactive elements. This approach, as opposed to “black box” static documents, empowers 70 
intuitive decision-making and case discussion, which may require an in-depth revision of the available 71 
information. Variants of clinical interest, such as those qualifying for genetic counseling referral or clinical 72 
trial allocation, appear automatically flagged according to CCE predefined criteria. Oncologists 73 
acknowledge the advantages of reports with modern user interface design, systematically structured and 74 
tailored to the needs of ongoing clinical initiatives, in a system that enables sharing the responsibility of 75 
treatment allocation with experts in a truly collaborative manner. Of note, we observed a learning curve to 76 
use the portal lasting for approximately 25 reviewed patients. After that, the amount of time devoted to 77 
discussing each patient’s case (more than 500 at the moment of writing this manuscript) rarely exceeds 78 
four minutes, which is key to scale the process.  79 
A precision oncology decision support tool must give access to the latest clinical actionability evidence 80 
and computational analytical tools. Data interpretation can benefit from a variety of publicly available 81 
genomics resources, but as variant information exchange standards have not yet been adopted by the 82 
community3, the MTBP implements an extensive data format harmonization to ensure their accurate 83 
aggregation. We interpret the patient’s germline and tumor variants in terms of both functional and 84 
predictive relevance, two distinct and complementary analyses required for the full range of decision-85 
making of a molecular tumor board. First, the variants’ functionality informs the need for genetic 86 
counselling referral when deleterious (pathogenic) germline events in actionable disease-causing genes 87 
are detected4–6. Importantly, this analysis also provides the necessary information for patient matching to 88 
clinical trials with “categorical” inclusion criteria – those that rely on estimating the functional effect of 89 
 
variants observed in drug targets, such as “activating” mutations in a given oncogene or “loss-of-function” 90 
alterations of a tumor suppressor. The MTBP classifies a variant as functionally relevant by integrating 91 
up-to-date evidence from multiple expert-curated knowledgebases, bona fide biological assumptions and 92 
bioinformatics predictions. Second, the predictive interpretation matches functionally relevant variants to 93 
biomarkers of disease diagnosis, prognosis and drug response reported at present7–9. In addition to on-94 
label prescribing, this informs off-label and experimental drug opportunities to be considered according to 95 
current knowledge. Decision support tools are especially useful for target-drug prioritization in complex 96 
molecular scenarios, such as tumors with co-occurring alterations known to interact and modify the 97 
efficacy of a given drug. The portal ranks the variants’ predictive relevance according to the ESMO’s 98 
Clinical Actionability of Molecular Targets scale10, which factors in the scientific evidence supporting the 99 
biomarker effect and gene-drug-disease interactions. As a resource to investigators outside of our 100 
network, we recently launched an open access version of the MTBP genomics interpretation pipeline 101 
(https://mtbp.org), which provides a general framework to classify the functional and predictive relevance 102 
of a given list of variants.  103 
We believe that adoption of cancer type-focused treatment guidelines or access to medical records 104 
equipped with clinical pathways are insufficient to meet the full potential of omics-guided precision 105 
oncology. Instead, the use of stand-alone health technology tools that can provide patient-centered 106 
predictive analyses moving beyond generic rules-based criteria will be increasingly important. We 107 
advocate that decision support systems driven by academic networks such as the MTBP facilitate the 108 
cross-institutional development of clinical trials and real-world data repositories, and accelerate the 109 
translation of biomarker discoveries to the clinics. In this regard, we are currently working to incorporate 110 
data from emerging biomarkers such as proteomics and digital pathology in our portal. In the near future, 111 
these systems will become learning platforms where novel data-to-decision models can be properly 112 
assessed and improved. For this to happen, healthcare stakeholders must collaborate to create 113 
seamlessly integrated “precision oncology information technologies” and invest in the assets necessary to 114 
maintain them.  115 
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Figure Legend 201 
 202 
The Molecular Tumor Board Portal automates a common NGS data capture, interpretation and reporting 203 
process across Cancer Core Europe centers, currently formed by the Cancer Research UK Cambridge 204 
Centre (Cambridge), German Cancer Research Center & National Center for Tumor Diseases 205 
 
(Heidelberg), Institut Gustave Roussy (Paris), Karolinska Institutet (Stockholm), National Cancer Institute 206 
(Milan), Netherlands Cancer Institute (Amsterdam) and Vall d’Hebron Institute of Oncology (Barcelona). 207 
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